Print
Email
Print Edition Stories
Rib-X Pharmaceuticals Inc., an antibiotics company in New Haven, Conn., has taken in a $20 million financing, led by Warburg Pincus LLC.
The company said in a press release that its new funding will be used to help bring its delafloxacin antibiotic drug to a Phase 2b study this year.
“In early 2011, we will begin a Phase 2b delafloxacin study to validate new objective endpoints for a near-term Phase 3 study and will initiate a long-term preclinical safety study with radezolid to demonstrate its key points of differentiation,” said Rib-X President and CEO Mark Leuchtenberger. “We also expect to nominate an initial development candidate with activity against multi-drug resistant Gram-negative bacteria from our Rχ-04 program in early 2011.”
In addition to delafloxacin, Rib-X’s IV and oral antibiotic option, the company also develops radezolid, a broad-use antibiotic, and R-04, its antibiotic intended for serious, multi-drug resistant bacteria.
Rib-X was founded in 2001 by Yale University colleagues Peter Moore, William Jorgensen and Thomas Steitz, winner of a portion of the 2009 Nobel Prize in Chemistry for his work describing the structure and function of the ribosome.
Leuchtenberger joined Rib-X last March and was profiled by Mass High Tech last year.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
